Rheumatoid Arthritis Treatment - Small Molecules, Biologics, Therapy III

Session Type: ACR Abstract Submissions
Tuesday, November 8, 2011: 9:00 AM-6:00 PM
Hall F2 - Poster Hall (McCormick Place West)
Papers:
Tocilizumab and Tumor Necrosis Factor Inhibitors in Biologic Switchers: Similar Drug Survival and Safety with Different Infection Profile in Routine Practice
Kazuki Yoshida1, Kazuo Matsui1, Hiroto Nakano1, Hideto Oshikawa1, Masako Utsunomiya1, Tatsuo Kobayashi1, Makiko Kimura1 and Mitsumasa Kishimoto2, 1Kameda Medical Center, Kamogawa City, Japan, 2St Luke`s International Hospital, Chuo-ku, Tokyo, Japan
Clinical Efficacy of Infliximab Is Maximized When Both Circulating TNF and IL-6 Are Suppressed In the Treatment of Rheumatoid Arthritis -Results From the RISING Study-
Tsutomu Takeuchi1, Yoshihiko Tatsuki2, Toshiro Yano2, Toru Yoshinari2, Nobuyuki Miyasaka3, Tohru Abe4 and Takao Koike5, 1School of Medicine, Keio University, Tokyo, Japan, 2Mitsubishi Tanabe Pharma Corporation, Osaka, Japan, 3Tokyo Med & Dent Univ, Tokyo, Japan, 4Saitama Medical School, Kawagoe-shi Saitama, Japan, 5Sapporo Medical Center NTT EC, Sapporo, Japan
Combination Therapy with Adalimumab+Methotrexate Significantly Improved Work Ability, Physical Function, Fatigue, and Other Patient-Reported Outcomes in Early Rheumatoid Arthritis: Results From a 26-Week Analysis
Paul Emery1, Arthur F. Kavanaugh2, Josef Smolen3, Mary A. Cifaldi4, Leonardo Chaves4, Benoit Guerette5, Vipin Arora4 and Ronald F. van Vollenhoven6, 1Chapel Allerton Hospital, Leeds, United Kingdom, 2University of California San Diego, San Diego, CA, 3Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 4Abbott Laboratories, Abbott Park, IL, 5Abbott, Rungis, France, 6The Karolinska Institute, Stockholm, Sweden
SC Abatacept Is Effective and Well Tolerated with Low Immunogenicity Following Temporary Withdrawal and Reintroduction in the ALLOW LTE (Evaluation of ABA Administered SubcutaneousLy in AduLts With Active RA: Impact of Withdrawal and Reintroduction)
Jeffrey L. Kaine1, Geoffrey S. Gladstein2, Ingrid Strusberg3, Manuel Robles4, Ramesh Pappu5, Ingrid Delaet5, Miranda Pans5 and Charles L. Ludivico6, 1Sarasota Arthritis Center, Sarasota, FL, 2New England Research Associates, Trumbull, CT, 3Instituto Reumatológico Strusberg, Cordoba, Argentina, 4Centro Médico Toluca, Metepec, Mexico, 5Bristol-Myers Squibb, Princeton, NJ, 6East Penn Rheumatology Association, East Stroudsburg, PA
Immunogenicity Is Low and Transient with Intravenous (IV) Abatacept Therapy: Results From a Large Pooled Analysis of 3985 Patients (pts) with Rheumatoid Arthritis (RA) and up to 8 Years’ Exposure
Michael E. Weinblatt1, Mark C. Genovese2, Michael H. Schiff3, Rene Westhovens4, Rieke Alten5, Ingrid Delaet6, Marleen Nys6, James Manning6 and Joel M. Kremer7, 1Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 2Stanford University, Palo Alto, CA, 3Rheumatology Division, University of Colorado, Denver, CO, 4University Hospital KU Leuven, Leuven, Belgium, 5Rheumatology Schlossparkklinik, Berlin, Germany, 6Bristol-Myers Squibb, Princeton, NJ, 7Albany Medical College and The Center for Rheumatology, Albany, NY
Tofacitinib (CP-690,550), An Oral Janus Kinase Inhibitor, As Monotherapy in Japanese Patients with Active Rheumatoid Arthritis: A 12-Week Phase 2b Study
Y. Tanaka1, T. Takeuchi2, H. Yamanaka3, M. Suzuki4, H. Nakamura4, S. Toyoizumi4, J. D. Bradley5 and S. H. Zwillich5, 1University of Occupational & Environmental Health, Kitakyushu, Fukuoka, Japan, 2Keio University School of Medicine, Tokyo, Japan, 3Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 4Pfizer Inc., Tokyo, Japan, 5Pfizer Inc., Groton, CT
Use of Disease-Modifying Anti-Rheumatic Drugs for Rheumatoid Arthritis in Quebec, Canada
Jean-Pascal Roussy1, Louis Bessette2, Sasha Bernatsky3, Elham Rahme3, Jean Légaré4 and Jean Lachaine1, 1University of Montreal, Montreal, QC, 2CHUL, Quebec, QC, 3McGill UHC/RVH, Montreal, QC, 4Arthritis Alliance of Canada, Neuville, QC
Remission Induction by Etanercept (ETN) Plus Methotrexate (MTX) Combination Therapy Versus ETN Monotherapy in Patients with Active Rheumatoid Arthritis Despite MTX Treatment
Hideto Kameda1, Ukitaka Ueki2, Kazuyoshi Saito3, Shouhei Nagaoka4, Toshihiko Hidaka5, Tatsuya Atsumi6, Michishi Tsukano7, Tsuyoshi Kasama8, Shunichi Shiozawa9, Yoshiya Tanaka3, Katsuaki Kanbe10, Eri Sato11, Hisashi Yamanaka12 and Tsutomu Takeuchi1, 1Keio University School of Medicine, Tokyo, Japan, 2Rheumatic and Collagen Disease Center, Sasebo, Japan, 3U Occupa & Environ Hlth, Kitakyushu, Japan, 4Yokohama Minami Kyosai Hospital, Yokohama, Japan, 5Zenjinkai Shimin-No-Mori-Hospital, Miyazaki, Japan, 6Hokkaido University, Sapporo, Japan, 7Kumamoto Hospital, Kumamoto, Japan, 8Showa University School of Med, Shinagawa-ku Tokyo, Japan, 9Kobe University Graduate School of Health Science and Medicine/ TThe Center for Rheumatic Diseases, Kobe University Hospital, Kobe, Japan, 10Medical Center East, Tokyo Women's Medical University, Tokyo, Japan, 11Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 12Tokyo Women's Medical Univ, Shinjuku-ku , Tokyo, Japan
Celecoxib, a Selective Cyclooxygenase-2 Inhibitor, Improves a Bone Resorption Marker in Postmenopausal Women with Rheumatoid Arthritis
Shigeyoshi Tsuji1, Tetsuya Tomita2, Takao Iwai1, Takanobu Nakase1, Masayuki Hamada1, Hideo Kawai1 and Hideki Yoshikawa2, 1Hoshigaoka Koseinenkin Hospital, Hirakata city, Japan, 2Osaka University Graduate School of Medicine, Suita Osaka, Japan
Safety of Rituximab in Combination with Other Biologic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis: 48-Week Data From SUNDIAL
William Rigby1, Philip J. Mease2, Ewa Olech3, Mark Ashby4 and Swati Tole4, 1Dartmouth Medical School, Lebanon, NH, 2Swedish Medical Center, Seattle, WA, 3Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Genentech, Inc., South San Francisco, CA
Switching of Biologic Disease-Modifying Antirheumatic Drugs During the First Year in Patients with Rheumatoid Arthritis in a Real-World Setting
Brian Meissner, Digisha Trivedi, Min You and Tony Hebden, Bristol-Myers Squibb, Plainsboro, NJ
Real-World Switching Patterns in RA Patients Receiving Abatacept, Adalimumab, Etanercept or Infliximab As Second-Line Biologic Therapy
Brian Meissner, Lisa Rosenblatt, Digisha Trivedi, Min You and Tony Hebden, Bristol-Myers Squibb, Plainsboro, NJ
Long-Term Safety of Rituximab in Rheumatoid Arthritis: Pooled Analysis of Patients in Clinical Trials with up to 9.5 Years of Treatment
Ronald F. van Vollenhoven1, Paul Emery2, Clifton O. Bingham3, Edward Keystone4, Roy M. Fleischmann5, Daniel E. Furst6, Nicola Tyson7, Neil Collinson7 and Patricia B. Lehane7, 1The Karolinska Institute, Stockholm, Sweden, 2Chapel Allerton Hospital, Leeds, United Kingdom, 3Johns Hopkins University, Baltimore, MD, 4University of Toronto, Toronto, ON, 5University of Texas, Dallas, TX, 6UCLA, Los Angeles, CA, 7Roche Products Limited, Welwyn Garden City, United Kingdom
Eight Year Results of Disease Activity Steered Treatment in a Large Recent Rheumatoid Arthritis Cohort: Clinical and Radiological Outcomes
Linda Dirven1, M. van den Broek1, N.B. Klarenbeek1, K.H. Han2, H.K Ronday3, P.J.S.M. Kerstens4, Tom W.J. Huizinga1, Willem F. Lems5 and C.F. Allaart1, 1Leiden University Medical Center, Leiden, Netherlands, 2Maasstad Hospital, Rotterdam, Netherlands, 3Haga Hospital, The Hague, Netherlands, 4Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, 5VU University medical center, Amsterdam, Netherlands
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BIIB023 (Anti-TWEAK) in Subjects with Rheumatoid Arthritis
Nicolas Wisniacki1, Vishala L. Chindalore2, Christine E. Codding3, Maria W. Greenwald4, Marianne L. Shaw5, Sergey Fitilev6, Olga Ershova7, Xiao Hu8, Timothy S. Zheng9, Lakshmi Amaravadi8, Ray Zhang9 and Linda C. Burkly8, 1Biogen Idec, Maidenhead, United Kingdom, 2Anniston Medical Clinic PC, Anniston, AL, 3Health Research of Oklahoma, Oklahoma City, OK, 4Desert Medical Advances, Palm Desert, CA, 5Duncansville, PA, 6M. Sechenov Moscow Medical Academy, Moscow, Russia, 7Clinical Hospital for Emergency Care, Moscow, Russia, 8Biogen Idec, Cambridge, MA, 9Biogen Idec Inc, Cambridge, MA
Response to Second-Line DMARDs and TNFi in Seropositive and Seronegative Patients in Early and Late Rheumatoid Arthritis Are Not the Same: Results From the CATCH Cohort and a Large, Established Rheumatoid Arthritis Database
Yang Cao, University of Western Ontario, London, ON, Ashley Bonner, McMaster University, Hamilton, ON, Lillian J. Barra, Schulich School of Medicine and Dentistry, London, ON, J. Carter Thorne, Southlake Regional Health Centre, Newmarket, Newmarket, ON, Boulos Haraoui, Institut de Rhumatologie, Montreal, QC, Gilles Boire, CHUS - Sherbrooke University, Sherbrooke, QC, Carol A. Hitchon, University of Manitoba, Winnipeg, MB, Nicole G. H. Le Riche, St. Joseph's Hospital, London, ON, Andrew E. Thompson, St. Josephs Health Ctr, London, ON, Edward Keystone, University of Toronto, Toronto, ON, Vivian Bykerk, Brigham and Women's Hospital, Boston, MA, Janet E. Pope, St. Joseph's Health Care, University of Western Ontario, London, ON and CATCH Investigators, Toronto, ON
Effect of Tocilizumab on Hematologic Markers Implicates Interleukin-6 Signaling in the Anemia of Rheumatoid Arthritis
John D. Isaacs, Newcastle University, Newcastle Upon Tyne, United Kingdom, Olivier Harari, Roche, Welwyn, United Kingdom, Uwe Kobold, Roche Diagnostics GmbH, Penzberg, Germany, Germany, C. Bernasconi, Roche, Basel, Switzerland and Janet S. Lee, Roche, Nutley, NJ
Comparison of Disease Characteristics of rheumatoid arthritis patients in Remission According to the DAS Criteria Versus the New ACR/EULAR Criteria in a Real-World Patient Population
Denis Choquette1, William G. Bensen2, Maqbool K. Sheriff3, John T. Kelsall4, Milton F. Baker5, John S. Sampalis6, Susan M. Otawa7 and Heidi Imhoff7, 1University of Montreal Hospital Research Centre (CRCHUM), Notre Dame Hospital Montreal, Montreal, QC, 2McMaster University, Hamilton, ON, Hamilton, ON, 3Nanaimo Regional General Hospital, Nanaimo, BC, 4Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, 5University of Victoria, Victoria, BC, 6McGill University & JSS Medical Research, Montreal, QC, 7Merck Canada Inc, Kirkland, QC
Golimumab Treatment Inhibits Progression in Joint Damage in Patients with Psoriatic Arthritis Regardless of Baseline Disease Severity
Arthur Kavanaugh, University of California San Diego, San Diego, CA, Dafna D. Gladman, University of Toronto, Toronto Western Hospital, Toronto, ON, Anna Beutler, Centocor R&D, a division of Johnson & Johnson Pharmaceutical Research & Development, LLC, Malvern, PA, Chenglong Han, Johnson & Johnson Pharmaceutical Services, LLC, Malvern, PA and GO-REVEAL Clinical Investigators
Optimism and Depressive Scores in Early Arthritis Patients Before and After Treatment with Methotrexate and a Tapered High Dose of Prednisone in the IMPROVED Study.
L. Heimans1, K.V.C. Wevers-de Boer1, K. Visser1, Tom W.J. Huizinga1, H.K Ronday2, M.L. Westedt3, T.H.E. Molenaar4, R.C. van der Mast1 and C.F. Allaart1, 1Leiden University Medical Center, Leiden, Netherlands, 2Haga Hospital, The Hague, Netherlands, 3Bronovo Hospital, The Hague, Netherlands, 4Groene Hart Hospital, Gouda, Netherlands
Sustained Inhibition of Structural Damage in Patients with Rheumatoid Arthritis and An Inadequate Response to Tumor Necrosis Factor Inhibitors Prior to Rituximab Treatment: 5-Year Data From the REFLEX Study
Edward Keystone1, Stanley B. Cohen2, Paul Emery3, Joel M. Kremer4, Maxime Dougados5, James E. Loveless6, Carol Chung7, Patricia B. Lehane8 and Helen Tyrrell8, 1University of Toronto, Toronto, ON, 2Metroplex Clinical Research Center, Dallas, TX, 3Chapel Allerton Hospital, Leeds, United Kingdom, 4Albany Medical College, Albany, NY, 5Rene Descartes University, Paris, France, 6St. Luke's Rheumatology, Boise, ID, 7Genentech, Inc., South San Francisco, CA, 8Roche Products Limited, Welwyn Garden City, United Kingdom
Evaluation of Remission Over 1 Year in Patients (pts) with Early Rheumatoid Arthritis (RA) Treated with Abatacept (ABA) Plus Methotrexate, According to Simplified Disease Activity Index (SDAI)
Josef Smolen1, J. Wollenhaupt2, Juan J. Gomez-Reino3, Walter Grassi4, Manuela Le Bars5, Corine Gaillez5, Coralie Poncet6, Ayanbola Elegbe7 and Rene Westhovens8, 1Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 2Schön Klinik Hamburg-Eilbek, Hamburg, Germany, 3Hospital Clinico Universitario, Santiago de Compostela, Spain, 4Università Politecnica delle Marche, Ancona, Italy, 5Bristol-Myers Squibb, Rueil Malmaison, France, 6Docs International, Sèvres, France, 7Bristol-Myers Squibb, Princeton, NJ, 8UZ Gasthuisburg, Leuven, Belgium
GLPG0634 Shows Selective Inhibition of JAK1 and Maintained JAK-STAT Suppression in Healthy Volunteers
Frédéric Vanhoutte1, René Galien2, Eva Vets3, Florence Namour2, Béatrice Vayssièrre2, Luc Van Rompaey1, Bart Smets1, Reginald Brys1, Piet Wigerinck1 and Gerben van 't Klooster1, 1Galapagos NV, Mechelen, Belgium, 2Galapagos SASU, Romainville, France, 3SGS, Antwerp, Belgium
Evaluation of Anti-Tumor Necrosis Factor Levels and Anti-Tumor Necrosis Factor Antibodies in Rheumatic Diseases Treated with Infliximab and Adalimumab; Preliminary Results From a Local Registry
José Rosas-Gómez de Salazar1, Francisca Llinares-Tello1, José M. Senabre-Gallego1, Gregorio Santos-Soler1, Carlos Santos-Ramírez2, Esteban Salas-Heredia1, Xavier Barber-Vallés3, Mabel Sánchez-Barrioluengo4, Juan Molina-García1, Nuria Llahí Vidal1 and Catalina Cano Pérez1, 1Hospital Marina Baixa, Villajoyosa, Spain, 2Hospital Marina Salud, Denia, Spain, 3University Miguel Hernández, Elche, Spain, 4Universitat Politècnica de València, Valencia, Spain
Open-Label, Pilot Study of the Safety and Clinical Effects of Rituximab in Patients with Rheumatoid Arthritis-Associated Interstitial Pneumonia
Eric L. Matteson1, Paul F. Dellaripa2, Jay H. Ryu1, Cynthia S. Crowson1, Thomas E. Hartman1 and Tim Bongartz1, 1Mayo Clinic, Rochester, MN, 2Brigham and Womens Hospital, Boston, MA
Efficacy and Safety of Tocilizumab As Monotherapy or in Combination with Nonbiologic Disease-Modifying Antirheumatic Drugs: A 24-Week Randomized Study in a United States Population
Michael E. Weinblatt1, Joel M. Kremer2, John J. Cush3, William F. C. Rigby4, Lichen Teng5, Natasha Singh5 and Raymond L. Malamet6, 1Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 2Albany Medical College and The Center for Rheumatology, Albany, NY, 3Baylor Research Institute, Dallas, TX, 4Dartmouth-Hitchcock Med Ctr, Lebanon, NH, 5Roche, Nutley, NJ, 6Genentech, South San Francisco, CA
Efficacy, Safety, and Improvements in Work Productivity and Daily Activities with Certolizumab Pegol After Incomplete Response to Disease-Modifying Anti-Rheumatic Drugs in Patients with Low to Moderate Disease Activity
Josef Smolen1, Paul Emery2, Gianfranco Ferraccioli3, Francis Berenbaum4, Owen Davies5, Oana Purcaru5, Johann Ambrugeat5, Barbara Bennett6 and Harald Burkhardt7, 1Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 2Chapel Allerton Hospital, Leeds, United Kingdom, 3Division of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy, 4Pierre and Marie Curie University, AP-HP St-Antoine Hospital, Paris, France, 5UCB, Brussels, Belgium, 6UCB, Smyrna, GA, 7Johan Wolfgang Goethe University, Frankfurt am Main, Germany
Improved Quality of Life and Productivity in Patients with Moderate or Severe Rheumatoid Arthritis Actively Switched to Treatment with Infliximab From Adalimumab or Etanercept Therapy
Roy M. Fleischmann1, Rebecca Bolce2, Jim Wang3, Mike Ingham2, Raphael J. DeHoratius2, Dennis Decktor2 and RESTART Clinical Investigators, 1MCRC, University of Texas, Dallas, TX, 2Janssen Services, LLC, Horsham, PA, 3Johnson & Johnson Pharmaceutical Research and Development, LLC, Belle Mead
Safety and Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis During More Than 5 Years of Therapy Observed in a Phase 3b and Post-Marketing Observational Study
Gerd-Rüdiger Burmester1, Marco Matucci-Cerinic2, Xavier Mariette3, Francisco Navarro-Blasco4, Uemit Oezer5, Sonja Kary5, Kristina Unnebrink5, Theresa Peterson6 and Hartmut Kupper5, 1Charité - University Medicine, Berlin, Germany, 2Univ Florence, Firenze, Italy, 3Université Paris-Sud Hôpital Bicêtre, Le Kremlin Bicêtre, France, 4Universitario de Elche, Alicante, Spain, 5Abbott, Ludwigshafen, Germany, 6Abbott, Abbott Park, IL
Long-Term Safety of Tocilizumab in Rheumatoid Arthritis Clinical Trials
Mark C. Genovese, Stanford University Medical Center, Palo Alto, CA, Anthony Sebba, University of South Florida, Palm Harbor, FL, Andrea Rubbert-Roth, University of Cologne, Cologne, Germany, Juan Scali, Durand University Hospital, Buenos Aires, Argentina, Moshe Zilberstein, Roche, Nutley, NJ, Liz Thompson, Roche, Welwyn, United Kingdom and Ronald F. van Vollenhoven, Karolinska University Hospital, Stockholm, Sweden
Comparison of Tocilizumab As Monotherapy or with Add-on Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis and An Inadequate Response to Previous Treatments
Vivian Bykerk1, Andrew Östör2, José Andrés Román Ivorra3, Jürgen Wollenhaupt4, Andrea Stancati5, Corrado Bernasconi5 and Jean Sibilia6, 1Brigham & Women's Hospital, Boston, MA, 2University of Cambridge, Cambridge, United Kingdom, 3Hospital Universitario La Fe, Valencia, Spain, 4Schön Klinik, Hamburg, Germany, 5Roche, Basel, Switzerland, 6CHU Hautepierre, Strasbourg, France
Effects of Tocilizumab Dose Escalation on Disease Activity in Adult Rheumatoid Arthritis Patients with Inadequate Response At 16 Weeks
Jeffrey R. Curtis1, Sarika Ogale2, Jenny Devenport2 and Denise Lepley2, 1University of Alabama at Birmingham, Birmingham, AL, 2Genentech, South San Francisco, CA
Long Term Anti Tnfa Therapy for Inflammatory Rheumatic Disease Is Associated with Increased Bone Mineral Density and Paradoxical Elevation of TRAP5b Serum Levels
Eric Toussirot1, Laurent Mourot2, Emilie Grandclement3, Daniel Wendling4 and Gilles Dumoulin3, 1Rheumatology and CIC Biotherapy 506 and EA 4266 Pathogens and Inflammation, Besançon, France, 2University of Franche Comté, Besançon, France, 3Department of Physiology, France, 4Minjoz University Hospital, Besancon, France
12 Month-Retrospective Analysis of Two Different Rituximab Retreatment Regimens in Rheumatoid Arthritis: Retreatment At Clinical Relapse Vs 6th Month Fixed Retreatment
Luca Quartuccio1, Franco Schiavon2, Domenico Biasi3, Valeria Carraro2, Viviana Ravagnani4, Ilaria Dal Forno4, Paola Masolini1, Elisa Mansutti1, Laura Corazza1, Leonardo Punzi5, Silvano Adami4 and Salvatore De Vita1, 1Rheumatology Clinic, DSMB, University of Udine, Udine, Italy, 2Rheumatology Clinic, University of Padova, Padova, Italy, 3Rheumatology Unit, University of Verona, Verona, Italy, 4Rheumatology Clinic, University of Verona, Verona, Italy, 5Rheumatology Unit, University of Padova, Padova, Italy
The Comparative Efficacy and Toxicity of Initial Disease-Modifying Anti-Rheumatic Drug Choices for Patients with Moderate-Severe Early Rheumatoid Arthritis: A Bayesian Network Meta-Analysis
Glen S. Hazlewood1, Cheryl CM Barnabe2, George A. Tomlinson1, Deborah Marshall3 and Claire Bombardier4, 1University of Toronto, Toronto, ON, 2Univ of Calgary Foothills Hosp, Calgary, AB, 3University of Calgary, Calgary, AB, 4Institute for Work & Health, Toronto, ON
Impact of Comorbidities on TNF Inhibitor Persistence in Rheumatoid Arthritis Patients : An Analysis of Korean National Health Insurance Claims Data
Soo-Kyung Cho1, Yoon-Kyoung Sung1, Chan-Bum Choi2, Jae Hoon Kim3, Jin Ju Kim4, Joo-Hyun Lee4, Young Bin Joo4 and Sang-Cheol Bae1, 1Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 2Hanyang University Hospital for Rheumatic Disease, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 3Hanyang University Hospital for Rheumatic Disease, Seoul, South Korea, 4Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
Perioperative Use of Anti-TNF Medications in Patients with Rheumatoid Arthritis Undergoing Total Knee Replacement
Beverly Johnson, Susan M. Goodman, Michael Alexiades and Lisa A. Mandl, Hospital for Special Surgery, New York, NY
Undetectable Rheumatoid Factor Following Treatment with Rituximab- What Is Clinical Significance?
Pravin Patil1, Julia Flint1, Elena Becerra-Fernandez1, Inmaculada de la Torre2, Geraldine Cambridge1, Maria J. Leandro1 and Jonathan CW Edwards1, 1University College of London, London, United Kingdom, 2Hospital Gregorio Maranon, Madrid, Spain
Definition of Treatment Response in Rheumatoid Arthritis Based on the Simplified and the Clinical Disease Activity Index
Daniel Aletaha, Medical University of Vienna, Vienna, Austria, José Martinez-Avila, Medical University of Vienna, Austria, Tore K. Kvien, Diakonhjemmet Hospital, Oslo, Norway and Josef S. Smolen, Krankenhaus Lainz, Vienna, Austria
Golimumab 3-Year Safety Update: An Analysis of Pooled Data From the Long Term Extensions of Randomized, Double-Blind, Placebo-Controlled Studies in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
Jonathan Kay1, Roy Fleischmann2, Edward Keystone3, Elizabeth C. Hsia4, Mittie K. Doyle4, Benjamin Hsu4, Michael Mack5, Anna Beutler5, Jürgen Braun6 and Arthur Kavanaugh7, 1University of Massachusetts Memorial Medical Center/University of Massachusetts Medical School, Worcester, MA, 2University of Texas Southwestern Medical Center, Dallas, TX, 3University of Toronto, Toronto, ON, 4Centocor R&D, a division of Johnson & Johnson Pharmaceutical Research & Development, LLC/Univ. of Pennsylvania School of Medicine, Malvern/Philadelphia, PA, 5Centocor R&D, a division of Johnson & Johnson Pharmaceutical Research & Development, LLC, Malvern, PA, 6Rheumazentrum Ruhrgebiet, Herne, Germany, 7University of California San Diego, San Diego, CA
Initial Combination Therapy with Adalimumab Plus Methotrexate Leads to Better Long-Term Outcomes in Patients with Advanced Rheumatoid Arthritis: Analysis of the Final 10-Year Results of An Open-Label Extension of a Phase 3 Trial
Edward Keystone1, Désirée van der Heijde2, Michael E. Weinblatt3, Neelufar Mozaffarian4, Benoit Guerette5, Hartmut Kupper6, Shufang Liu4, Benjamin Wolfe4 and Arthur Kavanaugh7, 1University of Toronto, Toronto, ON, 2Leiden University Medical Center, Leiden, Netherlands, 3Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 4Abbott, Abbott Park, IL, 5Abbott, Rungis, France, 6Abbott GmbH & Co KG, Ludwigshafen, Germany, 7University of California San Diego, San Diego, CA
Patients with Early Rheumatoid Arthritis (RA) Who Respond Well to Methotrexate Monotherapy Have Less Metacarpal Bone Loss, Measured by Digital X-Ray Radiogrammetry (DXR), Than Those Who Need Add-on Therapy. Findings From a Randomized Trial
Hamed Rezaei1, Saedis Saevarsdottir1, Kristina Forslind2, Pierre Geborek3, Ingemar F. Petersson3, Sofia Ernestam4, Johan Bratt4 and Ronald F. van Vollenhoven1, 1The Karolinska Institute, Stockholm, Sweden, 2Helsingborgs Lasarett and Lund University, Lund, Sweden, 3Lund University, Lund, Sweden, 4Karolinska University Hospital, Stockholm, Sweden
Relevance of Involvement of Tofacitinib in T Cell Subsets to Clinical Courses in Patients with Rheumatoid Arthritis
Koshiro Sonomoto, Kunihiro Yamaoka, Satoshi Kubo, Keisuke Maeshima, Ippei Miyagawa, Kazuhisa Nakano, Norifumi Sawamukai, Kazuyoshi Saito and Yoshiya Tanaka, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
Improvement in Disease Activity and Treatment Response Over 2 Years of Abatacept Treatment and Shifts to Improved Disease States in Patients with Early RA Who Switch From MTX
Rene Westhovens1, Juan J. Gomez-Reino2, Walter Grassi3, Corine Gaillez4, Manuela Le Bars4, Coralie Poncet5, Ayanbola Elegbe6 and Jurgen Wollenhaupt7, 1UZ Gasthuisburg, Leuven, Belgium, 2Hospital Clinico Universitario, Santiago de Compostela, Spain, 3Università Politecnica delle Marche, Ancona, Italy, 4Bristol-Myers Squibb, Rueil Malmaison, France, 5Docs International, Sèvres, France, 6Bristol-Myers Squibb, Princeton, NJ, 7Schön-Klinik Hamburg-Eilbeck, Hamburg, Germany
Rate of Anti-Cyclic Citrullinated Peptide Antibody and Rheumatoid Factor Seroconversion in Patients with Undifferentiated Arthritis or Early Rheumatoid Arthritis Treated with Abatacept
Tom W.J. Huizinga1, Paul Emery2, Rene Westhovens3, Manuela Le Bars4, Corine Gaillez4, Coralie Poncet5, Ayanbola Elegbe6 and Josef S. Smolen7, 1Leiden University Medical Center, Leiden, Netherlands, 2Chapel Allerton Hospital, Leeds, United Kingdom, 3UZ Gasthuisberg, Leuven, Belgium, 4Bristol-Myers Squibb, Rueil Malmaison, France, 5Docs International, Sévres, France, 6Bristol-Myers Squibb, Princeton, NJ, 7Medical University of Vienna and Hietzing Hospital, Vienna, Austria
Comparative Effectiveness and Time to Response Among Abatacept, Adalimumab, Etanercept and Infliximab for the Treatment of Rheumatoid Arthritis in a Real World Routine Care Registry
Yusuf Yazici, Division of Rheumatology, New York University School of Medicine and NYU Hospital for Joint Diseases, New York, NY, Maria T. Filopoulos, NYU Hospital for Joint Diseases, New York, NY and Christopher J. Swearingen, University of Arkansas for Medical Sciences, Little Rock, AR
Switching From Rituximab to Abatacept: Tolerance Data of 203 Patients Prospectively Followed up in the
Jacques-Eric Gottenberg, Strasbourg University Hospital, Strasbourg, France, Thierry Schaeverbeke, Pellegrin Hospital, Bordeaux, France, Philippe Gaudin, CHU Hôpital Sud, Grenoble Teaching Hospital, Echirolles, France, Liana E. Euller-Ziegler, L Archet Hospital (University), Nice CEDEX 3, France, Thao Pham, Sainte Marguerite Hospital, Marseille, France, Rene-Marc Flipo, Hopital R Salengro CHRU, Lille CEDEX, France, Alain G. Cantagrel, Hopital Purpan, Toulouse CEDEX 9, France, Eric Houvenagel, St Philibert Hospital, Lomme 59462, France, S. Redecker, Hospital University Abbeville, France, Xavier X. Le Loet, CHU de ROUEN, Rouen CEDEX, France, Pascal Claudepierre, Université Paris Est, Laboratoire d'Investigation Clinique (LIC) EA 4393, AP-HP, Hôpital Henri-Mondor, Rheumatology department, Creteil, France, Isabelle Pane, France, Philippe Ravaud, Hopital Hotel Dieu, Paris Descartes University, Paris, France and Xavier Mariette, Université Paris-Sud, Le Kremlin Bicetre, France
First Year Radiological Erosive Progression Is a New Predictor of Further Erosive Progression in Early Arthritis: Results of the ESPOIR Cohort
Gabriel Tobon, Unit of immunology, Brest, France, Alain Saraux, Brest Occidentale University, Brest, France, Cédric Lukas, Montpellier 1 University, Lapeyronie Hospital, 371, Avenue du Doyen Gaston Giraud, 34295 Montpellier Cedex 5, France, Montpellier, France, Frédérique Gandjbakhch, Hopital Pitié Salpétrière, Paris, France, Xavier Mariette, Université Paris-Sud, Le Kremlin Bicetre, France, Bernard G. Combe, Hopital Lapeyronie, Montpellier, France and Valerie Devauchelle-Pensec, Brest Occidentale university, Brest, France
New, Provisional American College of Rheumatology and European League Against Rheumatism Remission Criteria: Results From 2 Randomized, Controlled Golimumab Trials in Patients with Rheumatoid Arthritis  
Paul Emery, Chapel Allerton Hospital, Leeds, United Kingdom, Edward Keystone, University of Toronto, Toronto, ON, R. M. Fleischmann, University of Texas Southwestern Medical Center and Metroplex Clinical Research Center, Dallas, TX, M. C. Genovese, Stanford University Medical Center, Palo Alto, CA, Lars Klareskog, Karolinska Institutet, Stockholm, Sweden, Stephen Xu, Centocor R & D, a division of Johnson & Johnson Pharmaceutical Research & Development, LLC, Chenglong Han, Johnson & Johnson Pharmaceutical Services, LLC, Malvern, PA and Elizabeth C. Hsia, Centocor R&D, a division of Johnson & Johnson Pharmaceutical Research & Development, LLC, Malvern, PA
A Twelve-Week Exploratory Phase II Trial of GLPG0259 Versus Placebo in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
Rene Westhovens1, Filip De Keyser2, Dmitro Rekalov3, Evgeny L. Nasonov4, Johan Beetens5, Annegret Van der Aa5, Piet Wigerinck5, Florence Namour6, Frédéric Vanhoutte5 and Patrick Durez7, 1University Hospital KU Leuven, Leuven, Belgium, 2Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, 3Zaporizhzhia Regional Hospital, Zaporozhe, Ukraine, 4Institute of Rheumatology, Moscow, Russia, 5Galapagos NV, Mechelen, Belgium, 6Galapagos SASU, Romainville, France, 7Université Catholique de Louvain, Brussels, Belgium
Safety and Efficacy of Abatacept in Eight Rheumatoid Arthritis Patients with Chronic Hepatitis B
Paul S. Kim, University of California, Irvine, Orange, CA, Gerald Y. Ho, Arthritis/Osteoporosis Med Ctr, La Palma, CA, Pamela E. Prete, Long Beach VA Med Ctr, Long Beach, CA and Daniel E. Furst, UCLA, Los Angeles, CA
Efficacy of TNF Switch After Failure of One TNF Inhibitor – Results From a Nation-Wide Observational Study
Katerina Chatzidionysiou1, Jonas Eriksson2, Johan Askling3 and Ronald F. van Vollenhoven1, 1Karolinska Institute, Stockholm, Sweden, 2Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, 3Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Solna, Sweden
A Safety Analysis of Oral Prednisone As a Pre-Treatment for Rituximab in Rheumatoid Arthritis
John D. Carter1, Nancy Albritton1, S. Alireza Zarabadi2, Louis R. Ricca3, Joanne Valeriano-Marcet1, Frank B. Vasey4 and Anthony Sebba5, 1University of South Florida, Tampa, FL, 2Tampa Arthritis Center, Tampa, FL, 3University of South Florida College of Medicine, St Petersburg, FL, 4Wayne State Univ. Health Ctr., Detroit, MI, 5University of South Florida, Palm Harbor, FL
Characterization of Long-Term Responders to First Treatment Course of Rituximab (RTX) – Results From the CERERRA Collaboration
Elisabeth Lie1, Katerina Chatzidionysiou2, Evgeny L. Nasonov3, Galina Lukina3, Karel Pavelka4, Dan C. Nordström5, Matija Tomsic6, Cem Gabay7, Ioan Ancuta8, Piet LC van Riel9, Juan J. Gomez-Reino10, João E. Fonseca11, Merete L. Hetland12, Ulrik Tarp13, Tore K. Kvien1 and Ronald F. van Vollenhoven2, 1Diakonhjemmet Hospital, Oslo, Norway, 2Karolinska Institute, Stockholm, Sweden, 3Institute of Rheumatology, Moscow, Russia, 41Institute of Rheumatology, Department of Experimental Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, 5ROB-FIN, Helsinki University Central Hospital, Helsinki, Finland, 6University Medical Centre Ljubjana, Ljubljana, Slovenia, 7University Hospitals of Geneva, on behalf of the SCQM registry, Geneva, Switzerland, 8Cantacuzino Hospital, Bucharest, Romania, 9Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 10Hospital Clinico Universitario, Santiago, Spain, 11Lisbon Academic Medical Center, on behalf of Rheumatic Diseases Portuguese Register (Reuma.pt), Lisbon, Portugal, 12Copenhagen University Hospital at Glostrup, on behalf of DANBIO, Copenhagen, Denmark, 13Aarhus University Hospital, Aarhus, Denmark
Long-Term Tolerability of Tocilizumab for the Treatment of Rheumatoid Arthritis
Yoshihiro Hishitani, Toru Hirano, Yoshihito Shima, Atsushi Ogata, Masashi Narazaki, Keisuke Hagihara and Toshio Tanaka, Osaka University Graduate School of Medicine, Suita, Japan
A Multi-Biomarker Disease Activity Score (Vectra™DA algorithm score) Reflects Clinical Disease Activity and Tracks Response in a Japanese Rheumatoid Arthritis Population Treated with Anti-TNF Therapy
Shintaro Hirata1, Douglas J. Haney2, Guy Cavet2, Lyndal K. Hesterberg2, Norifumi Sawamukai1, Kunihiro Yamaoka3, Kazuyoshi Saito1 and Yoshiya Tanaka1, 1University of Occupational & Environmental Health, Japan, Kitakyushu, Japan, 2Crescendo Bioscience, Inc., South San Francisco, CA, 3University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
The Risk of Serious Infection with and without Anti-TNF Therapy in Rheumatoid Arthritis and Ankylosing Spondylitis: A Meta-Analysis
Hélène Cormier, Thomas Barnetche and Thierry Schaeverbeke, Pellegrin Hospital, Bordeaux, France
Rebalancing the IL-23/Th17 Axis and Regulatory T Cells in Arthritis by Depleting IRF5+ IL-23+ M1 Macrophages Using An Anti-Human DR5 Antibody
Jun Li1, Hui-Chen Hsu1, PingAr Yang1, Qi Wu1, Hao Li1 and John D. Mountz2, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Alabama at Birmingham and Birmingham VAMC, Birmingham, AL
Systematic Review and Network Meta-Analysis of Combination Therapy for Methotrexate-Experienced, Rheumatoid Arthritis Patients: Analysis of American College of Rheumatology Criteria Scores 20, 50 and 70
Michelle E. Orme1, Iain Fotheringham2, Stephen A. Mitchell2, Dean Spurden3 and Alex Bird3, 1ICERA consutling, United Kingdom, 2Abacus International, United Kingdom, 3Pfizer Ltd, Surrey, United Kingdom
Fucosylation Inhibitor, 2-D-Gal, Promotes Human Synovial Fibroblast Apoptosis and Is a Potent Suppressor of Arthritis in a TNF-α Tg Mouse Model In Vivo
Jun Li1, Hui-Chen Hsu1, PingAr Yang1, Qi Wu1 and John D. Mountz2, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Alabama at Birmingham and Birmingham VAMC, Birmingham, AL
Infliximab Is Associated with Improvement in Arterial Stiffness in Patients with Early Rheumatoid Arthritis – a Randomized Trial
Lai Shan Tam1, Qing Shang1, Edmund K. Li1, Ka Lai Lee2, Ying Ying Leung3, King Yee Ying4, Cheuk-Wan Yim5, Emily W. Kun6, Alexander M. Leung7, Martin Li1, Tena K. Li1, Tracy Y. Zhu1, Ricky K. Chui1, Lorraine Tseung1, Shui Lian Yu1, Woon Pang Kuan8 and Cheuk-Man Yu1, 1The Chinese University of Hong Kong, Hong Kong, Hong Kong, 2Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong, 3North District Hospital, Hong Kong, Hong Kong, 4Princess Margaret Hospital, Hong Kong, Hong Kong, 5United Christian Hospital, Hong Kong, Hong Kong, 6Tai Po Hospital, Hong Kong, Hong Kong, 7Queen Elizabeth Hospital, Hong Kong, Hong Kong, 8Hospital Selayang, Kuala Lumpur, Malaysia
Golimumab Use and Sustained Clinical Response in Patients with Active Rheumatoid Arthritis Previously Treated with Anti-Tumor Necrosis Factor Alpha Agents
Josef Smolen1, Jonathan Kay2, Robert Landewe3, Eric L. Matteson4, Norman B. Gaylis5, J. Wollenhaupt6, Frederick T. Murphy7, O. Zamani8, Yiying Zhou9, Elizabeth C. Hsia9 and Mittie K. Doyle9, 1Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 2University of Massachusetts Medical School, Worcester, MA, 3Academic Medical Center, Amsterdam, Netherlands, 4Mayo Clinic, Rochester, MN, 5Arthritis & Rheumatic Disease Specialties, Aventura, FL, 6Eilbeck Hospital, Hamburg, Germany, 7Altoona Ctr for Clinical Research, Duncansville, PA, 8Rheumazentrum Favoriten, Wien, Austria, 9Centocor R&D, a division of Johnson & Johnson Pharmaceutical Research & Development, LLC, Malvern, PA
Methotrexate Every Day Is Safe and Effective As Weekly Dosage
Ricardo Moreno-Valdes1, Marco Ulises Martinez-Martinez1, Enrique Cuevas-Orta1, Jorge Alcocer-Varela2 and Carlos Abud-Mendoza3, 1Hospital Central,, San Luis Potosí, Mexico, 2Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico city, Mexico, 3Hospital Central y Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosi, Mexico
B Cell Biomarkers Allow Prediction of Improving Response on Repeat Cycles of rituximab
Sudipto Das1, Edward M. Vital2, Shouvik Dass2, Maya H. Buch3, Andrew Rawstron2 and Paul Emery4, 1NIHR Leeds Musculoskeletal Biomedical Research Unit, University of Leeds and Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 2NIHR Leeds Biomedical Research Unit, University of Leeds and Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 3University of Leeds, Leeds, United Kingdom, 4Chapel Allerton Hospital, Leeds, United Kingdom
Pulmonary Adverse Events in a Cohort of Patients with Rheumatoid Arthritis Under Tnfa Blockers
Juan Antonio Martinez-Lopez1, Fredeswinda Romero1, Sandra Bermudez1, Jorge J. González López1, María Pérez Ferro1, Sheila Recuero1, Gema Díaz Moya1, Maria A. Contreras1, Gabriel Herrero-Beaumont2 and Olga Sanchez-Pernaute1, 1Jiménez Díaz Foundation University Hospital, Madrid, Spain, 2Jiménez Diaz Foundation University Hospital, Madrid, Spain
See more of: ACR Abstract Submissions

To see other sessions for this day, use the date buttons to the left.